Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.39 |
| ▸ | RGS4 | P49798 | 6/20 | 0.35 |
| ▸ | RGS8 | P57771 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942848 | 0.98 | RGS4 (0.36) | RAB9ALMNAHTTSMN1; SMN2NR2F2 | |
| SCHEMBL4114417 | 0.92 | RAB9A (0.37) | RAB9ALMNAHTTSMN1; SMN2NR2F2 | |
| SCHEMBL3386346 | 0.73 | CNR1 (0.44) | SMN1; SMN2RGS4RGS8TSHRALDH1A1 | |
| Bromide SCHEMBL944336 | 0.72 | CNR1 (0.43) | SMN1; SMN2RGS4RGS8TSHRALDH1A1 | |
| Bromide SCHEMBL961430 | 0.67 | CNR1 (0.37) | RAB9ASMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL5278781 | 0.66 | CNR2 (0.39) | RGS4ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3750688 | 0.63 | RAB9A (0.41) | RAB9ALMNAHTTSMN1; SMN2NR2F2 | |
| SCHEMBL9982876 | 0.63 | TNF (0.35) | TSHRALDH1A1TDP1L3MBTL1MAPT | |
| Bromide SCHEMBL4940305 | 0.63 | CYP1A1 (0.48) | RAB9ALMNAHTTSMN1; SMN2NR2F2 | |
| SCHEMBL4900911 | 0.62 | LMNA (0.30) | RAB9ALMNAHTTSMN1; SMN2NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865753-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875640-B2 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TRPV1 | RAB9A 3418/4885LMNA 2741/4885HTT 1691/4885 |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | RAB9A 1071/4885LMNA 3709/4885HTT 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.